Why the threshold criteria should not be modified for detection of possibly serious drug-induced hepatotoxicity in special groups of trial subjects

Authors


Correspondence to: J. R. Senior, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring MD 20993-0002, USA. E-mail: John.Senior@fda.hhs.gov

Ancillary